UK markets closed

Enanta Pharmaceuticals, Inc. (ENTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.32+0.09 (+0.68%)
At close: 04:00PM EDT
13.32 0.00 (0.00%)
After hours: 04:03PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 279.89M
Enterprise value -31.77M
Trailing P/E 436.70
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.78
Price/book (mrq)1.46
Enterprise value/revenue -0.43
Enterprise value/EBITDA 0.25

Trading information

Stock price history

Beta (5Y monthly) 0.49
52-week change 3-64.04%
S&P500 52-week change 321.23%
52-week high 337.75
52-week low 38.08
50-day moving average 314.68
200-day moving average 313.06

Share statistics

Avg vol (3-month) 3238.07k
Avg vol (10-day) 3177.88k
Shares outstanding 521.16M
Implied shares outstanding 621.16M
Float 813.34M
% held by insiders 16.10%
% held by institutions 1100.21%
Shares short (28 Mar 2024) 42.74M
Short ratio (28 Mar 2024) 410.82
Short % of float (28 Mar 2024) 413.79%
Short % of shares outstanding (28 Mar 2024) 412.97%
Shares short (prior month 29 Feb 2024) 42.09M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -187.77%
Operating margin (ttm)-193.78%

Management effectiveness

Return on assets (ttm)-22.89%
Return on equity (ttm)-56.11%

Income statement

Revenue (ttm)73.62M
Revenue per share (ttm)3.50
Quarterly revenue growth (yoy)-23.70%
Gross profit (ttm)N/A
EBITDA -139.58M
Net income avi to common (ttm)-138.24M
Diluted EPS (ttm)-6.57
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)337.15M
Total cash per share (mrq)15.94
Total debt (mrq)215.04M
Total debt/equity (mrq)112.07%
Current ratio (mrq)6.25
Book value per share (mrq)9.07

Cash flow statement

Operating cash flow (ttm)-92.5M
Levered free cash flow (ttm)-51.68M